900 Davis Drive
P.O. Box 14505
Research Triangle Park
About Eisai Inc.Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.
226 articles with Eisai Inc.
The battle of the bulge is ongoing and it appears that Americans are losing, according to a report from the U.S. Centers for Disease Control and Prevention. The report shows that Americans are losing height and gaining girth.
METAvivor and Presenting Sponsor Eisai Inc. Join Forces with AnaOno Intimates to Bring to Life the #ThisIsMBC Elements Campaign through Fashion
The fashion show, created to raise funds for metastatic breast cancer (MBC) research, featured MBC patient models, some of whom were featured in the Elements campaign.
BioArctic Announces That Eisai Will Initiate Phase 3 Confirmatory Study With BAN2401 in Early Alzheimer's Disease
BioArctic AB announced that Eisai stated at their Q3 FY2018 Financial Results Meeting on February 4, 2019 that a single Phase 3 confirmatory study of BAN2401 in early Alzheimer´s disease patients is under preparation and planned to be initiated within Eisai's FY2018 i.e. the first quarter 2019.
2/4/2019Eisai Co. and Purdue Pharma presented data at the Sleep Research Society’s Conference regarding their lemborexant for the treatment of insomnia. The meeting was held in Clearwater Beach, Florida.
Post-Hoc Analyses from Pivotal Phase 3 REFLECT Trial of LENVIMA® (lenvatinib) in Unresectable Hepatocellular Carcinoma to be Presented at 2019 Gastrointestinal Cancers Symposium
Eisai Inc. announced the presentation of four abstracts at the 2019 Gastrointestinal Cancers Symposium (#GI19), taking place in San Francisco from January 17-19, 2019
First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials
Eisai announced today that the first investigational drug candidate from their drug discovery collaboration with University College London (UCL) is to enter Phase I clinical trials for Alzheimer's disease (AD) in early 2019.
New Analyses Evaluate Long-Term Convulsive Seizure Freedom Rates With Use Of Adjunctive FYCOMPA® (perampanel) CIII In Adult Patients Presented at Annual Meeting of the American Epilepsy Society (AES)
In a real-world, observational, retrospective study of FYCOMPA as a first add-on therapy, 61% (19/31) of patients with generalized seizures achieved seizure freedom, with an overall retention rate of 85% (127/149) at 12 months
Eisai and METAvivor Team Up to Launch Elements as the Latest #ThisIsMBC Initiative at the 2018 San Antonio Breast Cancer Symposium
Eisai Inc. and METAvivor today announced the launch of Elements, a new initiative of the #ThisIsMBC campaign
Eisai to Present New Research on HALAVEN® (eribulin mesylate) Injection at 41st Annual San Antonio Breast Cancer Symposium
Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (marketed as HALAVEN®) will be presented during the 41st San Antonio Breast Cancer Symposium (SABCS). The symposium will be held from December 4-8, 2018, in San Antonio, Texas.
Eisai To Present FYCOMPA Long-Term Sustained Seizure Freedom And Pediatric Data At Upcoming American Epilepsy Society Annual Meeting
Eisai Inc. today announced that it will present FYCOMPA® (perampanel) CIII long-term seizure freedom and pediatric data at the upcoming American Epilepsy Society Annual Meeting taking place from November 30 to December 4 in New Orleans.
Eisai to Present Latest Data on LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination and Discovery of a Structurally Novel Class of STING Agonists at SITC's 33rd Annual Meeting
Eisai Inc. announced today the presentation of four abstracts at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C. from November 9-11.
10/25/2018After releasing positive topline data from the Phase II study of BAN2401 as a potential treatment for Alzheimer’s disease in July, some of the numbers did not hold up. This morning Biogen and its developmental partner Eisai attempted to provide an update on the information to show that the anti-a...
Eisai Inc. announced today that they have signed a value-based contract for FYCOMPA® (perampanel) CIII with Oklahoma Health Care Authority (OHCA) premised on reduction of hospitalizations of OHCA patients with epilepsy.
Eisai To Present Latest Data On Alzheimer's Disease / Dementia Pipeline At The 11th Clinical Trials On Alzheimer's Disease (CTAD) Conference
Additional Data from BAN2401 Phase 2 Results to be Presented
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
Long-term efficacy and safety evaluation in patients with insomnia, a sleep-wake disorder, met primary and key secondary efficacy objectives
10/17/2018Eisai Co. and Purdue Pharma announced topline results from their SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that 5 poster presentations reporting new research on human genetics guided drug discovery will be highlighted at the American Society of Human Genetics (ASHG) Conference 2018, in San Diego from Oct 16-20, 2018.
Eisai to Present LENVIMA® (lenvatinib) and HALAVEN® (eribulin) Data in a Variety of Advanced Cancers at ESMO 2018 Congress
New data on tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer to be presented in oral Proffered Paper session on Monday, Oct. 22 at 3:09 p.m. CEST
Eisai Announces New Data on the Effect of Anti-Obesity Agent BELVIQ® (lorcaserin HCl) on Prevention and Remission of Type 2 Diabetes Presented at the European Association for the Study of Diabetes (EASD) and Published in The Lancet
In secondary metabolic analyses of CAMELLIA-TIMI 61, patients with pre-diabetes who were treated with BELVIQ were less likely to develop diabetes and had a greater tendency to achieve normal blood glucose levels compared to patients treated with placebo
Eisai Announces FDA Approval Of FYCOMPA® in Pediatric Patients As Young As 4 Years Old For The Treatment Of Partial-Onset Seizures
Eisai Inc.. announced today that the Food and Drug Administration (FDA) expanded the indication of its antiepileptic drug FYCOMPA® (perampanel) CIII for monotherapy and adjunctive use in pediatric patients 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.